Bitcoin set for a rebound that could stretch toward $100000, BTIG says
WOONSOCKET, R.I. - CVS Health (NYSE:CVS) announced Wednesday that its board of directors has approved a quarterly dividend of $0.665 per share on the company's common stock.
The dividend will be payable on November 3, 2025, to shareholders of record as of October 23, 2025, according to a company press release.
CVS Health operates approximately 9,000 retail pharmacy locations and more than 1,000 walk-in and primary care medical clinics across the United States as of June 30, 2025. The healthcare company also manages a pharmacy benefits manager serving about 87 million plan members and provides senior pharmacy care to over 800,000 patients annually.
Additionally, the company offers health insurance products and related services to an estimated 37 million people, including Medicare Advantage offerings and a standalone Medicare Part D prescription drug plan.
The quarterly dividend announcement represents part of CVS Health's regular capital return program to shareholders.
In other recent news, CVS Pharmacy has agreed to a $12.25 million settlement with Massachusetts over allegations of overcharging the state's Medicaid program, MassHealth. The settlement addresses claims that CVS did not offer the same discounted prices available to cash-paying customers, resulting in higher charges for MassHealth. Meanwhile, CVS Health has decided not to include Gilead Sciences' new HIV prevention drug, Yeztugo, in its commercial plans. This decision was influenced by clinical, financial, and regulatory considerations, according to CVS.
Additionally, Cantor Fitzgerald has reiterated an Overweight rating for CVS Health, maintaining a price target of $78.00, reflecting confidence amid changes in the health insurance marketplace. Jefferies also reiterated its Buy rating on CVS Health, with a price target of $80.00, highlighting investor concerns ahead of CVS's second-quarter financial results. These developments reflect ongoing strategic decisions and market evaluations impacting CVS Health.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.